Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$13.56 - $20.78 $250,371 - $383,681
18,464 New
18,464 $266,000
Q3 2023

Nov 13, 2023

SELL
$18.22 - $25.85 $260,527 - $369,629
-14,299 Reduced 49.78%
14,428 $277,000
Q2 2023

Aug 10, 2023

SELL
$22.62 - $39.32 $561,247 - $975,607
-24,812 Reduced 46.34%
28,727 $730,000
Q1 2023

May 09, 2023

SELL
$30.17 - $41.11 $156,280 - $212,949
-5,180 Reduced 8.82%
53,539 $1.94 Million
Q4 2022

Feb 10, 2023

BUY
$36.43 - $49.4 $1.2 Million - $1.62 Million
32,849 Added 126.98%
58,719 $2.33 Million
Q3 2022

Nov 10, 2022

BUY
$40.66 - $53.03 $40,538 - $52,870
997 Added 4.01%
25,870 $1.21 Million
Q2 2022

Aug 05, 2022

BUY
$40.85 - $77.67 $60,417 - $114,873
1,479 Added 6.32%
24,873 $1.09 Million
Q1 2022

May 12, 2022

BUY
$59.95 - $92.06 $1.4 Million - $2.15 Million
23,394 New
23,394 $1.69 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $133M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.